- Home
- HRTX vs NPCE Comparison
HRTX vs NPCE Comparison
Compare HRTX & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- NPCE
- Stock Information
- Founded
- HRTX 1983
- NPCE 1997
- Country
- HRTX United States
- NPCE United States
- Employees
- HRTX N/A
- NPCE N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- HRTX Health Care
- NPCE Health Care
- Exchange
- HRTX Nasdaq
- NPCE Nasdaq
- Market Cap
- HRTX 276.1M
- NPCE 292.9M
- IPO Year
- HRTX 1987
- NPCE 2021
- Fundamental
- Price
- HRTX $1.35
- NPCE $9.15
- Analyst Decision
- HRTX Strong Buy
- NPCE Strong Buy
- Analyst Count
- HRTX 2
- NPCE 6
- Target Price
- HRTX $4.50
- NPCE $16.67
- AVG Volume (30 Days)
- HRTX 2.6M
- NPCE 205.3K
- Earning Date
- HRTX 08-08-2025
- NPCE 08-12-2025
- Dividend Yield
- HRTX N/A
- NPCE N/A
- EPS Growth
- HRTX N/A
- NPCE N/A
- EPS
- HRTX N/A
- NPCE N/A
- Revenue
- HRTX $149,694,000.00
- NPCE $88,570,000.00
- Revenue This Year
- HRTX $10.62
- NPCE $22.13
- Revenue Next Year
- HRTX $12.99
- NPCE $6.07
- P/E Ratio
- HRTX N/A
- NPCE N/A
- Revenue Growth
- HRTX 9.78
- NPCE 23.32
- 52 Week Low
- HRTX $1.04
- NPCE $5.45
- 52 Week High
- HRTX $2.68
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- NPCE 51.74
- Support Level
- HRTX $1.33
- NPCE $8.61
- Resistance Level
- HRTX $1.43
- NPCE $8.99
- Average True Range (ATR)
- HRTX 0.07
- NPCE 0.53
- MACD
- HRTX 0.02
- NPCE 0.11
- Stochastic Oscillator
- HRTX 45.45
- NPCE 75.00
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.